Pharma
ddobbs | June 30, 2009I have suspected for some time now that the band oddly close process designed to produce the DSM-V --- the diagnostic statistical manual that is psychiatry's diagnostic guide and Bible --- would create an explosion of some sort. But I didn't think it would explode quite so soon.
As Daniel Carlat outlines in a wonderful post â a must read, very high infotainment value â this is a pretty entertaining missing match. We have Allen Frances, a prominent psychiatrist who helped produce the previous edition of the DSM, leveling some very harsh criticisms of the process designed to produce a new…
ddobbs | June 30, 2009
[note: addition/corrections at bottom added an hour after orig post. additions underlined. deletions struckthrough. See *]
Meet the meta-placebo: A new study suggests that ADHD meds do much of their work by producing placebo effects -- and more constructive behavior -- among the parents, teachers, and other caretakers of the kids actually taking the meds. Via ScienceDaily:
A recent review of research by University at Buffalo pediatric psychologists suggests that [ADHD] medication, or the assumption of medication, may produce a placebo effect -- not in the children, but in their teachers,…
ddobbs | June 25, 2009Much much much ado on the web this week, on the too-many fronts I try to visit. From my list of notables:
Carl Zimmer, who clearly doesn't sleep, writes up a nice post about a Nature paper announcing Limusaurus, a newly discovered fossil that is, Zimmer notes, is "not -- I repeat NOT -- the missing link between anything"-- but nevertheless sheds some light on how dinos may have turned into birds (more or less). Bonus: Great pictures of Carl holding up three fingers.
Ed Yong, who seems to be drinking the same strength coffee as Carl Zimmer lately, looks at an interesting correlation: Hidden…
ddobbs | June 16, 2009Neuroskeptic offers an elegant unpeeling of a study seeming specifically designed to find a marketing-friendly distinction for a drug -- Abilify -- otherwise undistinguished.
Suppose you were a drug company, and you've invented a new drug. It's OK, but it's no better than the competition. How do you convince people to buy it?
You need a selling point - something that sets your product apart. Fortunately, with drugs, you have plenty of options. You could look into the pharmacology - the chemistry of how your drug works in the body - and find something unique there. Then, all you need to do is…
ddobbs | May 20, 2009
What's wrong -- but horribly expected -- in this picture? One week the CEO of Lilly attacks the idea of a public health insurance plan because it might reduce consumers' "ability to choose, in an informed way, from all the available alternatives." The next week, PhRMA, the trade group this CEO's company is a part of, launches a campaign to undermine comparative effectiveness studies -- which would produce the data necessary for informed consumer choice. If that's not enough, this campaign against collecting actual empirical effectiveness data, spearheaded under the astroturf group…
ddobbs | April 23, 2009Reading the Mindreading Studies - Science Progress seeks a handle on fMRI hype, hope, and horizons
The evolving Swine Flu story [Effect Measure] The skinny on a scary run of deadly swine flu, from people who've been doing this a while.
Green Issues Fade Is green losing its lustre?
Eli Lilly Tops List of Drug-Company Pay to Vermont Docs Altogether, 78 drug companies spent just shy of $3 million dollars in payments to health professionals in Vermont last year. This is a state of about 600,000 people, and only a few thousand doctors. Payments to psychiatrists, for instance, totaled $479,306.19…
ddobbs | April 15, 2009"You couldn't make this up: Cameras are being turned on the people paid to watch CCTV streams, to note which bits of surveillance footage they didn't see." via BoingBoing
The beauty of sand, close up -- a photo gallery at Discover.
Robots as recruitment to science. "If you stick a robot--I don't care if you're talking about grade school kids or high school students--if you put a robot in the middle of the room, there is something captivating about the technology." from Making Robots Personal - an interview with Tandy Trower of Microsoft Robotics. I find this particularly relevant as my 7-y.…
ddobbs | March 24, 2009Skip this post if you don't want to read a writer responding point by point to a self-indulgent, insubstantial attack by a major academic.
I should say right off that I've long admired the more measured critiques that J. Douglas Bremner, a PTSD researcher and professor of radiology and psychiatry at Emory University, has offered about the pharmaceutical industry's exploitation of the neurochemical model of depression. My regard for this work made his critique of attack on my article about PTSD, "The Post-Traumatic Stress Syndrome," all the more disappointing.
I'm not disappointed because…
ddobbs | March 5, 2009An ongoing topic here -- raised in depth here, and most recently here -- is how psychiatry is going to right itself from being knocked off-course and off-kilter by its overcozyness with pharma and a corresponding picture of mental disorder.
Psychiatrist Danny Carlat -- one of many dismayed by psychiatry's directtion over the last few years -- sees signs in a recent commentary in the American Journal of Psychiatry, signed by 26 highly prominent psychiatrists, that the discipline is starting to get it.
The key point of the commentary is stated in its title, "Conflict of Interest: An Issue…
ddobbs | March 5, 2009Philip Dawdy takes a interesting look at a new study of the safety of placebo arms in clinical trials of antidepressants in teens. My own quick scan of the study [which Dawdy makes available as pdf download] suggests it's full of great nuggets.
Its take-home: Placebo treatments produced remission rates of 48%, while the rate for active treatment was 59%. And, quite interestingly, the study concludes:
Patients who responded to placebo generally retained their response. Those who did not respond to placebo subsequently responded to active treatment at the same rates as those initiallyl…
ddobbs | March 4, 2009I'm having difficulty even reading, much less posting about, the river of stories about pharma and device industries, FDA regs, conflicts of interest, and so on. But I'll take a stab here at spotlighting the main events and making some sense of where this is headed. For I don't think it's just coincidence that brings in a few days an archetypal pharma scandal, an unexpected and emphatic Supreme court reversal, an underwear check administered to the entire faculty of the Harvard Medical School, and the decision to "make an example" of surgeons who took kickbacks for using medical devices.
The…
ddobbs | February 27, 2009I drove up to Montreal yesterday, and amid visits with anthropologist and Somatosphere founder Eugene Raikhel, anthropologist Allan Young, and Suparna Choudhury, talked about (among other things) the emerging new area of study they're calling "critical neuroscience."
What the heck is critical neuroscience? Well, one definition calls it
the attempt to assess and inform neuroscientific practice from a rich interdisciplinary perspective, and to categorize, evaluate and (begin to) manage the various risks resulting from neuroscience and its results and applications
.
Daniel Lende, one of the…
ddobbs | February 11, 2009A former: drug rep explains :
Samples are the number one influencer of the prescribing habits of doctors, and I proved this with my last pharma company, which was a very small one, where doctors could request samples simply by faxing in a form off of the company%u2019s website. I became the third best rep in sales out of 200 within six weeks, and never made one call on a doctor%u2019s office. I mailed these forms anonymously instead to the offices in my territory.
Dan A.
At DrugRepTime, hat tip to PharmaGossip.
ddobbs | February 10, 2009Marcia Angell makes it plain:
The fact that drug companies pay prescribers to be "educated" underscores the true nature of the transaction. Students generally pay teachers, not the reverse. The real intent is to influence prescribing habits, through selection of the information provided and through the warm feelings induced by bribery. Prescribers join in the pretence that drug companies provide education because it is lucrative to do so. Even free samples are meant to hook doctors and patients on the newest, most expensive drugs, when older drugs -- or no drug at all -- might be better for…
ddobbs | February 8, 2009The health-care system's maddening inefficiencies -- high per-capita spending with poorer overall health outcomes; tens of millions uninsured and tens of millions more underinsured; insane-making battles with insurers to get reimbursements you're entitled too -- are reason enough to spur reform.
But "The Big Fix," David Leonhardt's marvelous-but-long piece on the fiscal crisis in last week's Times Magazine, argues that these inefficiencies are a) a prime example of a vested elite's ability to manipulate the economy for its own good and b) one of the most serious obstacles to the nation's…
ddobbs | January 27, 2009
Pharma giant Pfizer got bigger on Monday, purchasing Wyeth Pharamceuticals for $65 billion in one of the few big business moves to get funding lately. This comes after several years of aggressive cost-cutting and huge layoffs at Pfizer, and was announced as the company released an annual report revealing a $2.3 billion settlement for offl-label marketing.
At least one Pfizer employee feels that Wyeth employees should be warned.
I feel sorry for the good people of Wyeth. You didn't ask to be gobbled up by this monster. As for myself, I was just to lazy/stupid/complacent to leave. I got…
ddobbs | January 27, 2009
Close on the heels of Lilly's $1.42 billion penalty for off-label marketing comes the news that Pfizer paid out $2.3 billion to settle similar allegations.
From FiercePharma
News of the Pfizer-Wyeth merger this morning drowned out some not so good news for the company. Just after announcing its $68 billion buyout of Wyeth, Pfizer published its 2008 fourth quarter earnings report. In it, Pfizer reveals a $2.3 billion charge to end investigations into allegations of off-label promotions of the company's COX-2 meds, including Bextra. That settlement caused a 90 percent reduction in Pfizer's…
ddobbs | January 22, 2009
In response to my post on himself, the NY Times, Zyprexa, Infinite Mind, etc.
ddobbs | January 20, 2009One theory about antidepressants is that they relieve depression by encouraging neurogenesis -- the creation of new neurons. Neuroskeptic reviews a study that argues against this idea.
the neurogenesis hypothesis has problems of its own. A new paper claims to add to what seems like a growing list of counter-examples: Ageing abolishes the effects of fluoxetine on neurogenesis.
The researchers, Couillard-Despres et. al. from the University of Regensburg in Germany, found that fluoxetine (Prozac) enhances hippocampal neurogenesis in mice - as expected - but found in addition that this only…
ddobbs | January 19, 2009I stirred some ire last week when I asserted that the Times (for -- disclosure dept -- whom I sometimes write) and similar mainstream papers offer a public good through their unique combination of a) access to information and 2) clout with the public and government. Several readers took me to task (see the comments section of the post linked above), arguing that these papers have failed their public mission by dropping the ball several times lately, most notably during the run-up to the Iraq War. "Let the dinosaur die," is the argument. In a similar vein, some science bloggers (see this post…